Press/Media
- 1 - 25 out of 539 results
Search results
-
Manuel Pellegrini: "I try to be apolitical. Football unites, the fan next door doesn't matter if he is communist, right-wing, republican..."
5/03/23
1 item of Media coverage
Press/Media
-
Manuel Pellegrini: "I try to be apolitical. Soccer unites, the fan next to me doesn't matter if he is a communist, right-winger, republican...".
4/03/23
1 item of Media coverage
Press/Media
-
Nivolumab plus cabozantinib superior to sunitinib in renal cell carcinoma
3/03/23
2 items of Media coverage
Press/Media
-
Nivolumab/Cabozantinib Shows Continued Benefit In Frontline Treatment of RCC
28/02/23
1 item of Media coverage
Press/Media
-
Nivolumab Plus Cabozantinib Demonstrates Positive Results for Renal Cell Carcinoma
27/02/23
1 item of Media coverage
Press/Media
-
Everyone knows everyone: the tangle of networks linking the Constitutional Council's experts
23/02/23
1 item of Media coverage
Press/Media
-
Nivolumab-plus cabozantinib improves outcomes in advanced renal cell carcinoma
23/02/23
2 items of Media coverage
Press/Media
-
Nivolumab Plus Cabozantinib Benefits Consistent at 3 Years for Renal Cell Carcinoma
21/02/23
1 item of Media coverage
Press/Media
-
Nivolumab/cabozantinib shows improvements in long-term survival for RCC
19/02/23
2 items of Media coverage
Press/Media
-
-
Positive results for Ipsen 's Cabometyx in combination with nivolumab
17/02/23
1 item of Media coverage
Press/Media
-
Basketball Legend Kareem Abdul-Jabbar Joins No Time to Wait Campaign to Raise Awareness of Atrial Fibrillation and its Symptoms
16/02/23
1 item of Media coverage
Press/Media
-
Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years' follow-up in first-line advanced renal cell carcinoma
13/02/23 → 16/02/23
5 items of Media coverage
Press/Media
-
Komo Plant Based Foods Reports Impressive Revenue Growth with a 160% Increase in Q2
16/02/23
1 item of Media coverage
Press/Media
-
Portage Biotech to Participate in Citi's 2023 Virtual Oncology Leadership Summit
15/02/23
1 item of Media coverage
Press/Media
-
How many are retired, where are they playing: a look back at the Golden Generation that won the 2015 Copa América
15/02/23
1 item of Media coverage
Press/Media
-
Cabometyx® In Combination With Nivolumab Shows Durable Survival Benefits At Over Three-Years' Follow-Up In First-Line Advanced Renal Cell Carcinoma
13/02/23 → 14/02/23
56 items of Media coverage
Press/Media
-
Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Shows Durable Survival with Over Three Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma
13/02/23 → 14/02/23
18 items of Media coverage
Press/Media
-
Cabometyx® in Combination with Nivolumab Shows Durable Survival Benefits At Over Three-years’ Follow-up in First-line Advanced Renal Cell Carcinoma
14/02/23
2 items of Media coverage
Press/Media
-
Gilead Demonstrates Transformative Potential Impact Of Antiviral Innovation at CROI 2023
14/02/23
1 item of Media coverage
Press/Media
-
-
Cabometyx and Opdivo show durable survival benefits in first-line advanced renal cell carcinoma
14/02/23
1 item of Media coverage
Press/Media